{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T10:20:14Z","timestamp":1709634014409},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,12,17]],"date-time":"2003-12-17T00:00:00Z","timestamp":1071619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label \/><jats:p>An Erratum has been published for this article in <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www3.interscience.wiley.com\/cgi-bin\/abstract\/107639690\/ABSTRACT\">Pharmacoepidemiology and Drug Safety 13(4) 2004, 267.<\/jats:ext-link>\n <\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To assess the safety of a plasma\u2010derived highly purified factor IX concentrate (Replenine\u00ae) in routine clinical use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Following guidelines entitled Safety Assessment of Marketed Medicines (SAMM), safety data were collected in the UK by retrospective review of the hospital notes of 114 patients who received an estimated 14.8 million IU of Replenine\u00ae. Included were 41 patients undergoing 44 surgical procedures or dental extractions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study detected a total of nine adverse events (AEs), four of which were possibly product\u2010related, four that were unrelated to the product and one whose causality was unknown. None of these cases had been notified to the manufacturer through conventional spontaneous reporting procedures. One patient was switched from Replenine\u00ae because of infusion site irritation, but no unexpected adverse reactions were noted. There were no reports of virus transmission or new factor IX inhibitor development. The mean factor IX recovery value was 1.44\u2009IU\/dl per IU\/kg (95%CI: 1.31\u20131.57\u2009IU\/dl per IU\/kg).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study was a practical application of the SAMM guidelines to the collection of pharmacovigilance data on patients with Haemophilia B. Replenine\u00ae is well tolerated in routine clinical practice. Published by John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.911","type":"journal-article","created":{"date-parts":[[2004,3,9]],"date-time":"2004-03-09T08:02:35Z","timestamp":1078819355000},"page":"187-195","source":"Crossref","is-referenced-by-count":8,"title":["A retrospective survey on the safety of Replenine\u00ae, a high\u2010purity factor IX concentrate"],"prefix":"10.1002","volume":"13","author":[{"given":"E. W.","family":"Gascoigne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. H.","family":"Dash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Harman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wilmot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,12,17]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Committee for Proprietary Medicinal Products. Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products. CPMP\/BPWG\/198\/95 rev.1. London 19 October2000."},{"key":"e_1_2_1_3_2","first-page":"181","article-title":"The history and conduct of safety assessment of marketed medicines studies in the UK","volume":"12","author":"Palmer L","year":"1998","journal-title":"Int J Pharm Med"},{"key":"e_1_2_1_4_2","first-page":"41","article-title":"Pharmacovigilance: paradise lost, regained or postponed?","volume":"29","author":"Rawlins MD","year":"1995","journal-title":"J Roy Coll Physicians London"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6840.1470"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04329.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb06738.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00035.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199412003-00006"},{"key":"e_1_2_1_10_2","article-title":"A new approach to pharmacovigilance in haemophilia: experience with Replenate\u00ae, a high\u2010purity factor VIII concentrate","author":"Gascoigne EW","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977213247"},{"key":"e_1_2_1_12_2","first-page":"25691","article-title":"Guideline for good clinical practice","volume":"62","author":"ICH Tripartite Guideline","year":"1997","journal-title":"Fed Regist"},{"key":"e_1_2_1_13_2","volume-title":"Report on the Annual Returns for 1996","author":"UK Haemophilia Centre Directors Organisation","year":"1998"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90874-3"},{"key":"e_1_2_1_15_2","first-page":"11284","article-title":"Clinical safety data management\u2014definitions and standards for expedited reporting","volume":"60","author":"ICH Harmonised Tripartite Guideline","year":"1995","journal-title":"Fed Regist"},{"key":"e_1_2_1_16_2","first-page":"2","volume-title":"Clinical Confidentiality","author":"Foster C","year":"2000"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.6.795"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.911","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.911","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T07:12:45Z","timestamp":1700205165000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,17]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1002\/pds.911"],"URL":"https:\/\/doi.org\/10.1002\/pds.911","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,17]]}}}